Brief: Ascelia Pharma Resolves On Rights Issue Of About SEK 105 Mln
11/07/2024 07:40
July 11 (Reuters) - Ascelia Pharma AB (publ) ACELP.ST :
* SAID ON WEDNESDAY IT DECIDED TO TO CARRY OUT RIGHTS OF
ABOUT SEK
105 MLN BEFORE ISSUE COSTS, WITH PREFERENTIAL RIGHTS FOR
EXISTING SHAREHOLDERS
* RIGHTS ISSUE IS SUBJECT TO APPROVAL AT EGM ON AUGUST 14,
2024
* PURPOSE IS TO SECURE RESOURCES REQUIRED TO COMPLETE NEW
DRUG
APPLICATION FOR ORVIGLANCE TO FDA, SECURE PARTNERSHIPS FOR
MARKET LAUNCH OF ORVIGLANCE
Source text for Workspace: urn:newsml:reuters.com:*:nMFN6Zxpkf
Further company coverage: ACELP.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))